15
April 2024
IXICO
plc
("IXICO"
or the "Company")
Life
Molecular Imaging - Neuraceq® Master Supply Agreement
IXICO plc (AIM: IXI),
the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, today provides information on its agreement with Life
Molecular Imaging (LMI) for the supply of LMI's
Neuraceq® Amyloid PET tracer (Florbetaben-18F) for use in
pharma-sponsored clinical trials. Neuraceq® is a
diagnostic agent that improves early detection and characterization
of chronic and life-threatening diseases such as Alzheimer's,
leading to better therapeutic outcomes and improved quality of
life.
As a result of its agreement with LMI, IXICO is
able to further extend its service offering to providing
Neuraceq® PET tracer supply to complement
IXICO's well-established PET imaging
services and image data analytics. LMI's provision of tracer
supply to imaging centres together with IXICO's oversight of
imaging will minimise the operational burden to trial sponsors and
will improve patient experience, ultimately driving study
eligibility and efficacy endpoint delivery.
Andrew Stephens, Chief Medical
Officer of Life Molecular Imaging, commented:
''We are
pleased to be partnering with IXICO to further strengthen access to
Neuraceq® to
clinical trials. We hope that our partnership will offer Sponsors
an additional streamlined route to tracer
supply.''
Giulio Cerroni, Chief Executive
Officer of IXICO, commented:
''IXICO is
committed to the continuous development of our suite of AI enabled
analytics and reader services for innovative new PET tracers and so
we are delighted to be partnering with LMI to improve access and
supply to LMI's Neuraceq. We anticipate that the extension of this
Neuraceq tracer co-ordination service from IXICO will be very well
received by our global biopharmaceutical
Sponsors."
For
further information please contact:
|
IXICO plc
|
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
+44
(0)20 3763 7499
|
|
|
|
|
|
|
This is an RNS Reach announcement and the
information contained is not considered to have a significant
impact on management's expectations of the Group's performance. RNS
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
About IXICO |
Advanced Analytics | Intelligent Insights.
IXICO is dedicated to delivering insights in
neuroscience to help transform the advancement of investigational
therapies for neurological diseases, such as Huntington's disease,
Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience by supporting pharmaceutical
companies across all phases of CNS clinical research. IXICO's goal
is to be a leading advocate of artificial intelligence in medical
image analysis.
IXICO has developed and deployed
breakthrough data analytics, at scale, through its remote access
technology platform, to improve the return on investment in drug
development and reduce risk and uncertainty in clinical trials for
the Company's pharmaceutical clients.
More information is available
on www.IXICO.com
About Life
Molecular Imaging (LMI)
Life Molecular Imaging (LMI) is an
international pharma company dedicated to developing and offering
novel cutting-edge PET radiopharmaceuticals for imaging of
neurodegenerative and cardiovascular diseases. The organization
strives to be a leader in the molecular imaging field. Our mission
is to pioneer innovative PET products that improve early detection
and characterization of chronic and life-threatening diseases,
leading to better therapeutic outcomes and improved quality of
life. By advancing novel PET radiopharmaceuticals for molecular
imaging, LMI is focusing on a key field of modern medicine. LMI is
an affiliate of Life Healthcare Group - an international
people-centred, diversified healthcare organization with four
decades of experience in the South African private healthcare
sector.
More information
about Life Molecular Imaging (LMI) at
https://life-mi.com
About Life Healthcare
Group https://www.lifehealthcare.co.za/
About
Neuraceq® (florbetaben 18F) https://neuraceq.com/
